



2nd RNA Horizons Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy

PRELIMINARY AGENDA

(as of June 22, 2025)

WEDNESDAY, OCTOBER 29, 2025

09:00 – 10:35	Session 1: RNA Delivery Innovation & Platforms
	Chair: Ernesto Guccione , USA
09:00 – 09:05	Opening Remarks
09:05 – 09:30	Nucleic Acid Therapeutic Unlabeled Reporter Assay (NATURA): A novel platform for high-throughput quantification of NATs' functional delivery and potency Ernesto Guccione Principal Investigator, The Guccione Lab, Icahn School of Medicine at Mount Sinai , USA
09:30 – 09:55	Modeling and Modulating Antitumor Immunity with RNA nanoparticles in 3D-Bioprinted Tumoroids Ronit Satchi-Fainaro Director, Cancer Biology Research Center, and Director, TAU Kahn 3D BioPrinting Initiative, TAU , IL
09:55 – 10:05	Start-Up Presentation DELiveri : Massive throughput screens to identify conjugates that promote cell delivery of nucleic acid therapeutics Yaniv Erlich CEO and Co-Founder, Eleven Therapeutics , IL
10:05 – 10:15	Start-Up Presentation Improved Delivery of RNAs for Extra-Hepatic Delivery Ruben Postel CSO & Scientific Founder, Sapreme Technologies , The Netherlands
10:15 – 10:35	Coffee Break, Visit the Exhibition & Poster Viewing
10:35 – 13:00	Session 2: RNA Splicing Mechanisms in Cancer
	Chair: Claudio Sette , Italy
10:35 – 11:00	SRSF1-regulated alternative splicing controls on oncogenic circuit in pancreatic cancer Adrian Krainer St. Giles Foundation Professor, Cold Spring Harbor Laboratory , New York, USA
11:00 – 11:25	Splicing dysregulation: Hallmark and therapeutic opportunity in cancer Claudio Sette Principal Investigator, Catholic University of the Sacred Heart, School of Medicine , Italy



2nd RNA Horizons Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy

11:25 – 11:50	Pseudoexon activation as a therapeutic approach Brage Storstein Andresen Head of Research, Brage Storstein Andresen Lab, University of Southern Denmark
11:50 – 12:15	Selected Talk
12:15 – 12:40	Selected Talk
12:40 – 12:50	Selected Talk
12:50 – 13:00	Selected Talk
13:00 – 14:00	Lunch Break, Visit the Exhibition & Poster Viewing
14:00 – 15:45	Session 3: Novel Therapeutic Applications of RNA Technology: Part 1
	Chair: Michal Lotem , IL
14:00 – 14:05	Opening Remarks
14:05 – 14:30	Dual-function oligonucleotide strategies for immunotherapy of acute myeloid leukemia Marcin Kortylewski Principal Investigator, The Kortylewski Lab, City of Hope , USA
14:30 – 14:55	Therapeutic approaches for HNRNPH2-Related Neurodevelopmental Disorder, an ultra-rare neurogenetic disorder Christopher Ricupero Assistant Professor, Columbia University Irving Medical Center , USA
14:55 – 15:20	Working with patient communities to develop ASO based therapies Yael Weiss Founder & CEO, Mahzi Therapeutics , USA
15:20 – 15:45	Targeting RNA splicing in immune-oncology and beyond Thomas Westbrook Executive Director, Therapeutic Innovation Center, Baylor College of Medicine , USA
15:45 – 16:15	Coffee Break, Visit the Exhibition & Poster Viewing
16:15 – 18:45	Session 4: Novel Therapeutic Applications of RNA Technology: Part 2
	Chair: Michal Lotem , IL
16:15 – 16:40	Developing RNA based approaches for the treatment of Pompe Disease and neurodegenerative conditions Emanuele Buratti Group Leader, Molecular Pathology Lab, ICGEB , Italy
16:40 – 16:50	Start-Up Presentation A transformative RNA (ASOs) based company for the treatment of pulmonary diseases Gili Hart CEO, SpliSense , IL



2nd RNA Horizons Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy

16:50 – 17:00	Start-Up Presentation Enabling Precision Medicine: From Liquid Biopsy to Antigen Discovery with Next-Gen Technologies Massimiliano Clamer Chairman & Founder, Immagina Biotechnology , Italy
17:00 – 17:45	Industry Panel Discussion: Shaping the Future of RNA Therapeutics: Innovation, Investment, and Impact Panelists: Yael Gruenbaum Cohen , aMoon Alpha , IL Michelle Lynn Hall , Associate Vice President, Eli Lilly and Company , USA Yaniv Erlich , CEO and Co-Founder, Eleven Therapeutics , IL
17:45 – 18:45	Poster Session

THURSDAY, OCTOBER 30, 2025

08:30 – 10:20	Session 5: Novel Therapeutic Applications of RNA Technology: Part 3
	Chair: Ernesto Guccione , USA
08:30 – 08:35	Opening Remarks
08:35 – 09:00	Targeting noncoding elements to boost haploinsufficient gene expression Igor Ulitsky Principal Investigator, Ulitsky Lab, Weizmann Institute of Science , IL
09:00 – 09:25	Small and long non-coding RNA transforming cell fates in the brain Anna Krichevsky Brigham and Women's Hospital, and Harvard Medical School , USA
09:25 – 09:50	Exploiting the dark genome to target drug-tolerant cells and improve anticancer immune therapies Eleonora Leucci Principal Investigator - RNA Cancer Biology Lab, KU Leuven , Belgium
09:50 – 10:15	Targeted delivery of therapeutic oligonucleotides for the treatment of neuromuscular diseases Oxana Beskrovnaya Chief Innovation Officer, Dyne Therapeutics , USA
10:15 – 10:25	Start-Up Presentation Cell-free RNA as a Mediator of Inflammation: New Paradigms for Therapeutic Intervention James Posada Chief Executive Officer, Resolve Therapeutics , USA
10:25 – 10:35	Start-Up Presentation Bispecific siRNA to reduce Cardiometabolic Risk Michael Khan Chief Executive Officer, Argonaute RNA , UK



2nd RNA Horizons Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy

10:35 – 10:45	Start-Up Presentation Targeting miR-22 with an Antisense Oligonucleotide: a new RNA-based paradigm for treating obesity Riccardo Panella , Chief Scientific Officer, Resalis Therapeutics , Italy
10:45 – 11:05	Coffee Break, Visit the Exhibition & Poster Viewing
11:05 – 13:25	Session 6: Innovations in Tumor Targeting and Cancer Immunotherapy Using RNA
	Chair: Rotem Karni , IL / USA
11:05 – 11:10	Opening Remarks
11:10 – 11:35	Rewriting the Message: RNA Splice Disruption Unmasks New Cancer Immunotherapy Targets Michal Lotem Head of The Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center , IL
11:35 – 12:00	Aberrantly spliced cancer proteoforms: If you can't beat them, eat them! Andrei Thomas-Tikhonenko Director of Experimental Pathology, Children's Hospital of Philadelphia , USA
12:00 – 12:25	Targeting RNA processing to induce neoantigen in cancer cells Rotem Karni Principal Investigator, Hebrew University-Hadassah Medical School , IL and University of Pennsylvania , USA
12:25 – 12:50	Translation Dysregulation in Cancer as a Source for Targetable Antigens Yardena Samuels Director, Moross Integrated Cancer Center, Samuels Lab, Weizmann Institute of Science , IL
12:50 – 13:15	A novel regulatory circuit required for tumor angiogenesis and cancer growth Claudia Ghigna Scientist, Institute of Molecular Genetics , Italy
13:15 – 13:25	Selected Talk
13:25 – 14:25	Lunch Break, Visit the Exhibition & Poster Viewing
14:25 – 15:45	Session 7: RNA Regulation & Translation in Cancer Biology
	Chair: Claudio Sette , Italy
14:25 – 14:30	Opening Remarks
14:30 – 14:55	RNA-binding proteins in melanoma progression Fátima Gebauer President of the RNA Society and Principal Investigator, Center for Genomic Regulation (CRG) , Spain
14:55 – 15:20	Exploiting RNA translation control to fight cancer resistance Caroline Robert Head of Dermatology, Gustave Roussy Institute , France



2nd RNA Horizons Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy

15:20 – 15:45	Ultra-conserved poison exons in SR protein splicing regulator genes: Do these operate as tumour suppressors or protect the functions of specific cell types? David Elliott Principal Investigator, Newcastle University , UK
15:45 – 16:10	Coffee Break, Visit the Exhibition & Poster Viewing
16:10 – 17:05	Session 8: RNA Regulation & Translation in Cancer Biology (cont.)
	Chair: Claudio Sette , Italy
16:10 – 16:20	Start-Up Presentation Targeting m6A-RNA Biology IN FTO-Dependent Cancers Amir Mor CSO, RNAble , IL
16:20 – 16:45	Breast cancer transcriptomics at the bulk, single cell and spatial levels Carlos Caldas Honorary Consultant in Medical Oncology, University of Cambridge , UK
16:45 – 16:55	Selected Talk
16:55 – 17:05	Selected Talk

FRIDAY, OCTOBER 31, 2025

09:00 – 10:20	Session 9: Computational & AI Applications in RNA Therapeutics
	Chair: Rotem Karni , IL / USA
09:00 – 09:05	Opening Remarks
09:05 – 09:30	AI-Driven Design: Unlocking Novel Mechanisms in RNA Therapeutics Tamar Grossman CEO, La Jolla Labs , USA
09:30 – 09:55	miRNA-based logic circuits encoded on self-amplifying RNA for highly specific cancer cell classification Ron Weiss Principal Investigator, The Weiss Lab, Massachusetts Institute of Technology , USA
09:55 – 10:20	Harnessing RNA-Driven Intelligence to Revolutionize Personalized Cancer Therapy Aron Popovtzer Director of the Sharett Institute of Oncology, Hadassah Medical Center , IL
10:20 – 10:45	Coffee Break, Visit the Exhibition & Poster Viewing



2nd RNA Horizons Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy

10:45 – 12:30	Session 10: Computational & AI Applications in RNA Therapeutics (cont.)
	Chair: Rotem Karni , IL / USA
10:45 – 11:10	Decoding Cancer Complexity: Machine Learning and Transcriptomic Signatures Shai Rosenberg Head of the Computational Medicine Service, Hadassah Hebrew University Medical Center , IL
11:10 – 11:20	Start-Up Presentation Utilizing Machine Learning to Unlock RNA Delivery Yogev Debbi Co-Founder & CEO, Mana.bio , IL
11:20 – 11:30	Selected Talk
11:30 – 11:40	Selected Talk
11:40 – 12:30	Concluding Remarks & Symposium Closure
12:30 – 13:00	Lunch